WGS Company Profile and Key Details

WGS has shown weak momentum, losing -16.4% over the past week and -17.58% over the past quarter, though year-to-date performance is down -23.36%. Short-term trend indicators are bullishly aligned (SMA20 -8.79%, SMA50 -25.77%, SMA200 -26.16%). The stock’s 14-day RSI is 35.3 (weak momentum), while the ATR of 6.4 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -52.37% below its high and over 47.51% above its low. Average 10-day trading volume of 672.62 thousand shares is below the 3-month average of 983.84 thousand, indicating normal recent market interest.

GeneDx Holdings Corp. has 28.73 million shares outstanding. The public float is 20.46 million shares, elevated short interest at 25.36% of float. This equals 3.63 million shares. The short ratio is 3.84 days. Institutional investors hold 131.61% of the float. Insiders own 12.31%. MOUNT SINAI HEALTH SYSTEM, INC. holds 94.61 million shares, Casdin Eli has 14.29 million shares and Meister Keith A. has 4.18 million shares. Over the past six months, insider transactions show balanced activity. They sold 34.01 thousand shares across 13 transactions.

GeneDx Holdings Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$140.16. This means the shares are trading below this model’s fair value.

GeneDx Holdings Corp. (NASDAQ:WGS) closed at $78.08 USD, losing -$1.07 (-1.35%) from the previous close of $79.15. The stock is currently mid-range between its 52-week high and low $32.21 and $170.87. With a market capitalization of about $2.33 billion, GeneDx Holdings Corp. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.98). Key stats such as the average daily volume over the past year has been around 992.29 thousand shares, volume is running light vs its 52-week average. Headquartered in Stamford, CT, GeneDx Holdings Corp. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Katherine A. Stueland, the company employs approximately 1,300 people and listed since November 04, 2020. GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient.

GeneDx Holdings Corp. generated EPS of -$0.74 over the past year. Five-year average earnings growth is 94.57%. Wall Street analysts project EPS growth of 29.61% annually over the next five years. The latest quarter delivered EPS of $0.01. The next quarter is forecast at $0.00. Next year's EPS is expected at $53.86. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 16 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $200.00 to $63.00. The high target offers 156.15% upside. The low target suggests -19.31% downside. The mean target is $127.70. This offers 63.55% upside. GeneDx Holdings Corp. earnings surprise history is a mixed track record. The quarter that ended August 03, 2026, missed forecasts by -105.32%. The prior quarter beat by 366.67%. Over the last six quarters, Apple has recorded several small beats. These include 154.55% in April 30, 2025.

GeneDx Holdings Corp. trades at a P/E ratio of -21.45, slightly below the S&P 500 average, with a price-to-sales ratio of 5.12 and a price-to-book ratio of 9.5 trading at moderately above to book value. The P/FCF stands at -30.72, also below market averages.

GeneDx Holdings Corp. (NASDAQ:WGS) shares are down -23.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows GeneDx Holdings Corp. trading at a premium to the broader market with a P/E of -21.45. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $91.30, suggesting 16.93% upside. Our AI forecast model points to short-term strength (22.13% over two weeks), a medium-term fall (-4.18% over three months), and a longer-term gain (51.32% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that GeneDx Holdings Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 22.13%, with price expected at $95.36 by August 28, 2026, within a range of $92.27 to $98.43 3-Month Outlook: Projected fall of -4.18%, reaching $74.82 by November 12, 2026, with a range of $68.13 to $80.35. 1-Year Outlook: Projected gain of 51.32%, with price at $118.15 by August 13, 2027, within a range of $106.79 to $127.46.